Head and neck cancer is increasingly prevalent world-wide, and claims the lives of 1500 Australians each year. These deaths are largely attributable to a lack of targeted therapies. The only new therapy that has improved long term survival of head and neck cancer patients is immunotherapy. There is increasing data indicating that invoking the body’s immune system is a novel and effective cancer therapy. Immunotherapy, aims to harness the bodies own immune system to target head and neck cancers.
- Providing novel immune-based therapy for recurrent/metastatic Naso-Pharyngeal Cancer (NPC)
- A pilot study of an old drug with a new use – prochlorperazine to improve anti-EGFR therapy in squamous cell carcinoma of the mucosa
- Develop and test immunotherapy to prevent and treat HPV associated head and neck cancers
- Novel Diagnostic and Adjunct Therapeutic Strategies to Improve ADCC mediated Monoclonal Antibody Therapy
- Key Personnel
- Prof Rajiv Khanna
- Prof Ben Panizza
- Prof Sandro Porceddu
- Dr Fiona Simpson
- Prof Denis Moss
- Prof Dora Kwong
- Dr Janice Tsang.